Valuation
- Market cap
- 148,928,000
- Revenue TTM
- $70,390,000
- Net income TTM
- $-43,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -62.47%
- Debt to equity
- 1.03
Trading
- Volume
- 551,800
- Avg volume
- 1,224,264
- Day's range
- $1.35 – $1.41
- Shares out
- 109,506,000
- Stochastic %K
- 42%
- Beta
- 2.55
- Analysts
- Strong Sell
- Price target
- $6.33
Company profile
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scale...
Show more
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 421 8100
- Website
- https://www.codexis.com
- Address
- 200 Penobscot Drive, Redwood City, United States
Latest news
No headlines yet.
